Compare DexCom, Inc. (DXCM) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Williams Companies Inc — how do they compare? DexCom, Inc. trades at $83.83 (market cap $31.86B), while Williams Companies Inc trades at $72.66 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 2.8× DexCom, Inc.'s market cap, and Williams Companies Inc pays a 2.9% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Williams Companies Inc for 58 Days on average.
| DXCM | WMB | |
|---|---|---|
Market Cap | $31.86B | $88.48B |
Volume | 3,607,070 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $92.34 | $79.40 |
52-Week Low | $54.84 | $56.51 |
Typical Hold Time | 62 Days | 58 Days |
Enterprise Value | $31.32B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Williams Companies (WMB) trades at $72.68, up 1.71% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while Q2 narrowly missed. Technical indicators signal bullish momentum with support at $71-$72 and resistance at $73-$74. The company benefits from stable fee-based revenues and strategic positioning in natural gas infrastructure.
WMB presents a compelling investment case with strong cash flow generation, 79% analyst buy ratings, and $87.27 price target upside. Key risks include energy market volatility and high debt levels. The AI-driven data center growth provides tailwinds for natural gas demand, supporting long-term revenue stability. Investors should weigh the attractive dividend yield against exposure to commodity price fluctuations and capital expenditure requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
